Tiziana Life Sciences Announces MOU With King Abdullah International Medical Research Center And Foundation For Neurologic Diseases For Trial Of Intranasal Foralumab With Anti-CD20 Therapy In Relapsing-Remitting MS

Benzinga Newsdesk www.benzinga.com Positive 90.3%

Neg 0% Neu 0% Pos 90.3%

Comments

No comments yet. Be the first!